Compass Therapeutics (CMPX) Invested Capital (2018 - 2021)

Compass Therapeutics has reported Invested Capital for 3 years, with the latest figure at $3.7 million in Q3 2021.

• Quarterly Invested Capital fell 49.82% year-over-year to $3.7 million in Q3 2021, while the trailing twelve-month figure through Jun 2022 was $3.7 million (down 83.29% YoY) and the FY2020 annual result came in at $7.5 million, up 33.91% from the prior year.
• Invested Capital eased to $3.7 million in Q3 2021 per CMPX's latest filing, from $7.5 million in the prior quarter.
• Over five years, Invested Capital peaked at $7.5 million in Q1 2021 and troughed at $3.7 million in Q3 2021.
• A 3-year average of $6.5 million and a median of $7.5 million in 2020 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2020 and 2021: Invested Capital soared 33.91% in 2020, then sank 49.82% in 2021.
• Over 3 years, Invested Capital stood at $5.6 million in 2019, then jumped by 33.91% to $7.5 million in 2020, then slumped by 49.86% to $3.7 million in 2021.
• According to Business Quant data, Invested Capital over the past three periods registered $3.7 million, $7.5 million, and $7.5 million for Q3 2021, Q1 2021, and Q4 2020 respectively.